CAJ | 학술논문

目的建立激素抗体组合微阵列检测方法，为垂体腺瘤患者及无症状高风险人群提供血清学早期筛查的新方法。方法通过对微阵列芯片制备条件进行摸索，选择出泌乳素、生长激素和促甲状腺素的单克隆抗体作为芯片反应时的最佳制备条件及检测体系后，将其合理组合固定在固相载体的表面而制备出低密度激素抗体蛋白微阵列，建立激素抗体组合微阵列芯片检测法，并对该方法的特异性、灵敏度、重复性、精密度和交叉反应进行初步评价，比较其与AxSYM全自动免疫分析仪的相关性。结果成功确定了激素抗体组合微阵列的制作条件，包括选择琼脂糖凝胶玻片作为点样载体，确定3种激素抗体包被浓度、点样缓冲液、固定时间等；优化了反应体系中的各种条件；得出了多种激素抗体组合微阵列检测方法从制作到反应结果分析的完整体系。结论本研究初步建立了多种激素抗体组合微阵列检测方法，并对其进行了方法学评价，该方法学的建立不仅为临床激素检测提供了一种新途径，也为以后将更多的相关检测项目纳入研究创造了条件。
목적건립격소항체조합미진렬검측방법，위수체선류환자급무증상고풍험인군제공혈청학조기사사적신방법。방법통과대미진렬심편제비조건진행모색，선택출비유소、생장격소화촉갑상선소적단극륭항체작위심편반응시적최가제비조건급검측체계후，장기합리조합고정재고상재체적표면이제비출저밀도격소항체단백미진렬，건립격소항체조합미진렬심편검측법，병대해방법적특이성、령민도、중복성、정밀도화교차반응진행초보평개，비교기여AxSYM전자동면역분석의적상관성。결과성공학정료격소항체조합미진렬적제작조건，포괄선택경지당응효파편작위점양재체，학정3충격소항체포피농도、점양완충액、고정시간등；우화료반응체계중적각충조건；득출료다충격소항체조합미진렬검측방법종제작도반응결과분석적완정체계。결론본연구초보건립료다충격소항체조합미진렬검측방법，병대기진행료방법학평개，해방법학적건립불부위림상격소검측제공료일충신도경，야위이후장경다적상관검측항목납입연구창조료조건。
Objective To establish a methods of protein microarray technology for parallel analysis of hormone,so as to achieve a serological screening tool for pituitary adenoma patients and asymptomatic high -risk groups of populations .Methods By choosing the conditions of the antibodies microarray fabrication , we arranged prolactin,growth hormone,thyrotropin monoclonal antibody on the surface fo the solid phase .And we finally finished the fabrication of this kind of low-density antibody microarray system .At the same time,we evaluated this method′s specificity,sensitivity,stablity,and precision,and compared the method with AxSYM chemoluminescence analyzer . Results We successfully identified protein microarray production conditions , identified three kinds of antibody hormone concentration ,solution buffer ,incubation time;to optimize the a variety of conditions of the reaction system;to draw the hormone combinations protein microarray detection methods ,and identified the whole production and data analysising system .Conclusions This research established a method of hormone antibody microarray detection system and applied it in pituitary adenoma patients screening .This was not only providing a new way for clinical hormone testing ,but also creating the conditions for bring into more relevant test items within the scope in the future .